
Opinion|Videos|June 20, 2024
The Role of ctDNA in Genitourinary Cancer
Toni Choueiri, MD, and the Oncology Brothers discuss the role of circulating tumor DNA in treatment paradigms for patients with genitourinary cancers.
Advertisement
Advertisement
Related to this article

A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.

The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.

Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
2
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
3
Crossover to Bezuclastinib Plus Sunitinib Improves Disease Control in Pretreated GIST
4
New ACS Guidelines Push for Earlier Prostate Cancer Screening
5

